Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of MT1013 Injection in Hemodialysis Patients With Secondary Hyperparathyroidism
CTR20243499Phase 2Active
- Sponsor
- Shaanxi Micot Technology Co., Ltd.
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of MT1013 in secondary hyperparathyroidism (SHPT) (3 arms), sponsored by Shaanxi Micot Technology Co., Ltd. Primary endpoint: Proportion of subjects with >30% reduction in mean pre-dialysis serum intact PTH from baseline during efficacy assessment period. Started Nov 2024; status: active.
02
Drugs
MT1013
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on CTR20243499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243499.